Pasireotide for malignant insulinoma

被引：40

作者：

Tirosh, Amit ^{[1
,2
]}

Stemmer, Salomon M. ^{[2
,3
]}

Solomonov, Evgeny ^{[4
]}

Elnekave, Eldad ^{[3
]}

Saeger, Wolfgang ^{[5
]}

Ravkin, Yelena ^{[6
]}

Nir, Kobi ^{[7
]}

Talmor, Yeela ^{[8
]}

Shimon, Ilan ^{[1
,2
]}

机构：

[1] Rabin Med Ctr, Endocrine Inst, Beilinson Campus, IL-4941492 Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

[3] Rabin Med Ctr, Davidoff Ctr, Inst Oncol, Petah Tiqwa, Israel

[4] Rivka Ziv Med Ctr, Surg, Sefad, Israel

[5] Univ Hamburg, Inst Neuropathol, Hamburg, Germany

[6] Clalit Hlth Serv, Tel Aviv, Israel

[7] Novartis Pharma Serv, Petah Tiqwa, Israel

[8] Rabin Med Ctr, Internal Med F, Petah Tiqwa, Israel

来源：

HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2016年 / 15卷 / 02期

关键词：

Hypoglycemia; Insulinoma; Neuroendocrine; Pasireotide; SOMATOSTATIN RECEPTOR; EVEROLIMUS; RELEASE; PHASE-3;

D O I：

10.14310/horm.2002.1639

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin analogs octreotide and lanreotide have limited ability to control the hypoglycemic events. Pasireotide is a multi-receptor targeted somatostatin-analog with improved affinity for SSTR5. There is to date no reported treatment experience with this drug in such tumors. CASE DESCRIPTION: A 72-year-old patient with a G2 stage IV insulinoma, who underwent excision of the primary pancreatic tumor and multiple hepatic metastases, required further treatment for recurrent hypoglycemic events. The glycemic control achieved with pasireotide LAR was better compared with lanreotide and everolimus. However, none of these treatments showed tumor anti-proliferative effects. CONCLUSIONS: Pasireotide monthly injections achieved improved glycemic control in a patient with malignant insulinoma and recurrent hypoglycemic events compared with other medical treatments.

引用

页码：271 / 276

页数：6

共 10 条

[1] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [J].

Bruns, C ;

Lewis, I ;

Briner, U ;

Meno-Tetang, G ;

Weckbecker, G .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :707-716

[2] A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease [J].

Colao, Annamaria ;

Petersenn, Stephan ;

Newell-Price, John ;

Findling, James W. ;

Gu, Feng ;

Maldonado, Mario ;

Schoenherr, Ulrike ;

Mills, David ;

Salgado, Luiz Roberto ;

Biller, Beverly M. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :914-924

[3] Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial [J].

Gadelha, Monica R. ;

Bronstein, Marcello D. ;

Brue, Thierry ;

Coculescu, Mihail ;

Fleseriu, Maria ;

Guitelman, Mirtha ;

Pronin, Vyacheslav ;

Raverot, Gerald ;

Shimon, Ilan ;

Lievre, Kayo Kodama ;

Fleck, Juergen ;

Aout, Mounir ;

Pedroncelli, Alberto M. ;

Colao, Annamaria .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (11) :875-884

[4] Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers [J].

Henry, Robert R. ;

Ciaraldi, Theodore P. ;

Armstrong, Debra ;

Burke, Paivi ;

Ligueros-Saylan, Monica ;

Mudaliar, Sunder .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08) :3446-3453

[5] The pathophysiological consequences of somatostatin receptor internalization and resistance [J].

Hofland, LJ ;

Lamberts, SWJ .

ENDOCRINE REVIEWS, 2003, 24 (01) :28-47

[6] SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells [J].

Kailey, Balrik ;

van de Bunt, Martijn ;

Cheley, Stephen ;

Johnson, Paul R. ;

MacDonald, Patrick E. ;

Gloyn, Anna L. ;

Rorsman, Patrik ;

Braun, Matthias .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2012, 303 (09) :E1107-E1116

[7] Glycemic Control in Patients with Insulinoma Treated with Everolimus [J].

Kulke, Matthew H. ;

Bergsland, Emily K. ;

Yao, James C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :195-197

[8] Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - Predominance of receptor subtype 4 [J].

Portela-Gomes, Guida Maria ;

Stridsberg, Mats ;

Grimelius, Lars ;

Rorstad, Otto ;

Janson, Eva Tiensuu .

ENDOCRINE PATHOLOGY, 2007, 18 (02) :79-85

[9] Everolimus for Advanced Pancreatic Neuroendocrine Tumors. [J].

Yao, James C. ;

Shah, Manisha H. ;

Ito, Tetsuhide ;

Bohas, Catherine Lombard ;

Wolin, Edward M. ;

Van Cutsem, Eric ;

Hobday, Timothy J. ;

Okusaka, Takuji ;

Capdevila, Jaume ;

de Vries, Elisabeth G. E. ;

Tomassetti, Paola ;

Pavel, Marianne E. ;

Hoosen, Sakina ;

Haas, Tomas ;

Lincy, Jeremie ;

Lebwohl, David ;

Oberg, Kjell .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06) :514-523

[10] Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5 [J].

Zambre, Y ;

Ling, ZD ;

Chen, MC ;

Hou, X ;

Woon, CW ;

Culler, M ;

Taylor, JE ;

Coy, DH ;

Van Schravendijk, C ;

Schuit, F ;

Pipeleers, DG ;

Eizirik, DL .

BIOCHEMICAL PHARMACOLOGY, 1999, 57 (10) :1159-1164

← 1 →